The evidence base for growth hormone effectiveness in children

Endocrine Development

Volumn 18, Issue , 2010, Pages 23-39

  Kelnar, Christopher J H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

BODY HEIGHT; BONE AGE; CHILD; CHILD HEALTH; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HORMONAL THERAPY; HUMAN; MEDICAL DECISION MAKING; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

CHILD; EVIDENCE-BASED MEDICINE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; PEDIATRICS; PROFESSIONAL PRACTICE;

EID: 84925854063     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000316125     Document Type: Review

References (64)

1. Kelnar CJH: Evidence-based child health - SIGN and NICE. Arch Dis Child Educ Pract Ed 2008; 93:190-198.
2. Moyer V, Elliott E: Preface; in Moyer V, Elliott E, Davis R, et al (eds): Evidence-Based Paediatrics and Child Health. London, BMJ Books, 2000.
3. Stylianou C, Kelnar CJH: The Introduction of Successful Insulin Treatment for Diabetes [commentary on Banting FG, Best CH, Collip JB, Campell WR, Fletcher AA: Pancreatic extracts in the treatment of diabetes mellitus. CMAJ 1922; 12:141-146]. The James Lind Library (www. jameslindlibrary.org).
4. Collins R, MacMahon S: Reliable assessment of the effects of treatment on mortality and major morbidity. I. Clinical trials. Lancet 2001;357:373-380.
5. Tanner JM: Fetus into Man. Boston, Harvard University Press, 1978.
6. Centers for Disease Control (CDC): Fatal degenerative neurologic disease in patients who received pituitary-derived human growth hormone. MMWR Morb Mortal Wkly Rep 1985;34:359-60, 365-366.
7. Powell-Jackson J, Weller RO, Kennedy P, Preece MA, Whitcombe EM, Newsom-Davis J: Creutzfeldt-Jakob disease after administration of human growth hormone Lancet 1985;ii:244-246.
8. Gibbs CJ Jr, Joy A, Heffner R, Franko M, Miyazaki M, Asher DM, Parisi JE, Brown PW, Gajdusek DC: Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone N Engl J Med 1985;313:734-738.
9. Brown P, Gajdusek DC, Gibbs CJ Jr, Asher DM: Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy N Engl J Med 1985;313:728-731.
10. Wilton P: Adverse events reported in KIGS; in Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Paediatrics - 20 Years of KIGS. Basel, Karger, 2007, pp 432-441.
11. MacMahon S, Collins R: Reliable assessment of the effects of treatment on mortality and major morbidity. II. Observational studies. Lancet 2001; 357:455-456.
12. Drake AM, Kelnar CJH: The evaluation of growth and the identification of growth hormone deficiency. Arch Dis Child 2006;91:ep61-ep67.
13. Obara-Moszýska M, Kedzia A, Korman E, Niedziela M: Usefulness of growth hormone (GH) stimulation tests and IGF-I concentration measurement in GH deficiency diagnosis. J Pediatr Endocrinol Metab 2008;21:569-579.
14. Kelnar CJH: Pride and prejudice - stature in perspective. Acta Paediatr Scand 1990;370(suppl):5-15.
15. Dawkins R: Gaps in the mind; in A Devil's Chaplain - Selected Essays. London, Weidenfeld & Nicolson, 2003.
16. Asher R: Straight and crooked thinking in medicine. BMJ 1954;ii:460-462.
17. Carroll L (Charles Lutwidge Dodgson): Through the Looking-Glass, and What Alice Found There. 1871.
18. Wit J-M, Ranke MB, Kelnar CJH (eds): ESPE Classification of Paediatric Endocrine Diagnoses. Horm Res Spec Ed 2007;68(suppl 2):1-120.
19. Noble D: The Music of Life - Biology beyond Genes. Oxford, Oxford University Press, 2006.
20. Sweeney K, Kernick D: Clinical evaluation: constructing a new model for post-normal medicine. J Eval Clin Pract 2002;8:131-138.
21. Dawkins R: Hierarchical organisation: a candidate principle for ethology; in Bateson PPG, Hinde RA (eds): Growing Points in Ethology. Cambridge University Press, 1976, pp 7-54.
22. Welsby PD: Evidence-based medicine, guidelines, personality types, relatives and absolutes. J Eval Clin Pract 2002;8:163-166.
23. Georgiou A: Data information and knowledge: the health informatics model and its role in evidencebased medicine. J Eval Clin Pract 2002;8:127-130.
24. Martin S, Rice N, Smith PC: The Link between Healthcare Spending and Health Outcomes - Evidence from English Programme Budgeting Data. London, The Health Foundation, 2007.
25. Malenka DJ, Baron JA, Johansen S, Wahrenberger JW, Ross JM: The framing effect of relative and absolute risk. J Gen Intern Med 1993;8:543-548.
26. Cave CB, Bryant J, Milne R: Recombinant growth hormone in children and adolescents with Turner syndrome. Cochrane Database Syst Rev CD003887, 2003.
27. Baxter L, Bryant J, Cave CB, Milne R: Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev CD003887, 2007.
28. Stephure DK, Canadian Growth Hormone Advisory Committee: Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial J Clin Endocrinol Metab 2005;90: 3360-3366.
29. Carel JC: Growth hormone in Turner syndrome: twenty years after, what can we tell our patients? J Clin Endocrinol Metab 2005;90:3930-3934.
30. Vimalachandra D, Craig JC, Cowell C, Knight JF: Growth hormone for children with chronic renal failure. Cochrane Database Syst Rev CD003264, 2001.
31. Vimalachandra D, Craig JC, Cowell CT, Knight JF: Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials. J Pediatr 2001;139:560-567.
32. Vimalachandra D, Hodson EM, Willis NS, Craig JC, Cowell C, Knight JF: Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev CD003264, 2006.
33. Hindmarsh PC: Endocrine assessment and principles of endocrine testing; in Kelnar CJH, Savage MO, Saenger P, Cowell CT (eds): Growth Disorders, ed 2. London, Hodder Arnold, 2007, pp 219-228.
34. Hailey JA, Bath LE, Kelnar CJH: Idiopathic short stature - diagnostic and therapeutic dilemmas. Royal Society of Medicine Current Medical Literature - Growth Hormone and Growth Factors 1999;14:61-65.
35. Kelnar CJH, Albertsson-Wikland K, Hintz RL, Ranke MB, Rosenfeld RG: Should we treat children with idiopathic short stature? Horm Res 1999;52:150-157.
36. Juul A, Bernasconi S, Chatelain P, Hindmarsh P, Hochberg Z, Hokken-Koelega A, de Muinck Keizer-Schrama SMPF, Kiess W, Oberfield S, Parks J, Strasburger CJ, Volta C, Westphal O, Skakkebaek NE: Diagnosis of growth hormone (GH) deficiency and the use of GH in children with growth disorders. Horm Res 1999;51:284-299.
37. Downie AB, Mulligan J, Stratford RJ, Betts PR, Voss LD: Are short normal children at a disadvantage? The Wessex Growth Study. BMJ 1997; 314:97-100.
38. Rekers-Mombarg LT, Busschbach JJ, Massa GG, Dicke J, Wit JM: Quality of life of young adults with idiopathic short stature: effect of growth hormone treatment. Dutch Growth Hormone Working Group. Acta Paediatr 1998;87:865-870.
39. Sandberg DE, Brook AE, Campos SP: Short stature: a psychosocial burden requiring GH therapy? Pediatrics 1994;94:832-840.
40. Zimet GD, Owens R, Dahms W, Cutler M, Litvene M, Cuttler L: Psychosocial outcome of children evaluated for short stature. Arch Pediatr Adolesc Med 1997;151:1017-1023.
41. Bryant J, Cave C, Milne R: Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev CD004440, 2003.
42. Bryant J, Baxter L, Cave CB, Milne R: Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev CD004440, 2007.
43. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM on behalf of the 2007 ISS Consensus Workshop Participants: Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008;93:4210-4217.
44. Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P: Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res 2008;18:89-110.
45. Wit JM, Reiter EO, Ross JL, Saenger PH, Savage MO, Rogol AD, Cohen P: Idiopathic short stature: management and growth hormone treatment. Growth Horm IGF Res 2008;18:111-135.
46. Haverkamp F, Ranke MB: The ethical dilemma of growth hormone treatment of short stature: a scientific theoretical approach. Horm Res 1999;51: 301-304.
47. Panpanich R, Garner P: Growth monitoring in children. Cochrane Database Syst Rev CD001443, 2000.
48. Garner P, Panpanich R, Logan S: Is routine growth monitoring effective? A systematic review of trials. Arch Dis Child 2000;82:197-201.
49. Voss LD, Mulligan J, Betts PR, Wilkin TJ: Poor growth in school entrants as an index of organic disease: the Wessex Growth Study. BMJ 1992;305: 1400-1402.
50. Ahmed ML, Allen AD, Sharma A, Macfarlane JA, Dunger DB: Evaluation of a district growth screening programme: the Oxford Growth Study. Arch Dis Child 1993;69:361-365.
51. Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M: Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994;125:29-35.
52. Van den Broeck J, Hokken-Koelega A, Wit JM: Validity of height velocity as a diagnostic criterion for idiopathic growth hormone deficiency and Turner syndrome. Horm Res 1999;51:68-73.
53. Van Buuren S, van Dommelen P, Zandwijken GR, Grote FK, Wit JM, Verkerk PH: Towards evidence- based referral criteria for growth monitoring. Arch Dis Child 2004;89:336-341.
54. Hall DMB: Growth monitoring. Arch Dis Child 2000;82:10-15.
55. Hall DMB, Elliman D: Health for All Children, ed 4. Oxford, Oxford University Press, 2003.
56. Van Buuren S, Bonnemaijer-Kerkhoffs DJ, Grote FK, et al: Many referrals under Dutch short stature guidelines Arch Dis Child 2004;89:351-352.
57. Grote FK, van Dommelen P, Oostdijk W, et al: Developing evidence-based short stature guidelines for referral for short stature. Arch Dis Child 2008;93:212-217.
58. Kelnar CJH, Stanhope R Height prognosis in girls with central precocious puberty treated with GnRH analogues. Clin Endocrinol 2002;56:295-296.
59. Miles A, Bentley P, Polychronis A, Grey JE, Melchiorri C: Recent developments in the evidencebased healthcare debate. J Eval Clin Pract 2001;7: 85-89.
60. Miles A, Grey JE, Polychronis A, Melchiorri C: Critical advances in the evaluation and development of clinical care. J Eval Clin Pract 2002;8:87-102.
61. Miles A, Grey JE, Polychronis A, Price N, Melchiorri C: Current thinking in the evidence-based health care debate. J Eval Clin Pract 2003;9:95-109.
62. Miles A, Grey JE, Polychronis A, Price N, Melchiorri C: Developments in the evidence-based health care debate - 2004. J Eval Clin Pract 2004; 10:129-142.
63. Miles A, Loughlin M: Continuing the evidencebased health care debate in 2006. The progress and price of EBM. J Eval Clin Pract 2006;12:385-398.
64. Miles A, Loughlin M, Polychronis A: Medicine and evidence: knowledge and action in clinical practice. J Eval Clin Pract 2007;13:481-503.